公开(公告)号：WO2017112824A2

公开(公告)日：2017-06-29

申请号：PCT/US2016/068138

申请日：2016-12-21

Applicant: AMGEN INC.

Inventor： YIE, Junming ,  SHI, Donghui ,  LLOYD, David J. ,  WANG, Jinghong ,  SIVITS, JR., Glenn N. ,  VENIANT-ELLISON, Murielle M. ,  KOMOROWSKI, Renee ,  AGRAWAL, Neeraj ,  BATES, Darren L. ,  CLAVETTE, Brandon C. P. ,  FOLTZ, Ian N. ,  HO, Shu-yin ,  MURAWSKY, Christopher ,  MIN, Xiaoshan ,  WANG, Zhulun

IPC: C07K16/28

CPC classification number: C07K16/2869 ,  A61K9/0019 ,  A61K38/1703 ,  A61K38/26 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

Abstract translation: 提供了使用对GIPR多肽特异的抗原结合蛋白治疗代谢疾病和病症的方法。 在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常，葡萄糖水平升高，胰​​岛素水平升高和糖尿病性肾病。 在某些实施方案中，抗原结合蛋白与GLP-1受体激动剂联合给药。

公开(公告)号：WO2012170438A3

公开(公告)日：2012-12-13

申请号：PCT/US2012/040941

申请日：2012-06-05

Applicant: AMGEN INC. ,  LI, Yang ,  STEVENS, Jennitte ,  KING, Chadwick, Terence ,  FOLTZ, Ian ,  KANNAN, Gunasekaran ,  YIE, Junming ,  HU, Shaw-Fen, Sylvia

Inventor： LI, Yang ,  STEVENS, Jennitte ,  KING, Chadwick, Terence ,  FOLTZ, Ian ,  KANNAN, Gunasekaran ,  YIE, Junming ,  HU, Shaw-Fen, Sylvia

IPC: C07K16/28 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  C07K14/71

Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

公开(公告)号：WO2018136440A1

公开(公告)日：2018-07-26

申请号：PCT/US2018/013918

申请日：2018-01-16

Applicant: AMGEN INC.

Inventor： CHENG, Yuan ,  NETIROJJANAKUL, Chawita ,  HOLDER, Jerry Ryan ,  WU, Bin ,  FALSEY, James R. ,  HERBERICH, Bradley J. ,  SHAM, Kelvin ,  MIRANDA, Leslie P. ,  LU, Shu-Chen ,  VENIANT-ELLISON, Murielle M. ,  STANISLAUS, Shanaka ,  YIE, Junming ,  XU, Jing

IPC: A61K39/395 ,  C07K16/28 ,  A61P3/10

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：WO2017112824A8

公开(公告)日：2017-06-29

申请号：PCT/US2016/068138

申请日：2016-12-21

Applicant: AMGEN INC.

Inventor： YIE, Junming ,  SHI, Donghui ,  LLOYD, David J. ,  WANG, Jinghong ,  SIVITS, JR., Glenn N. ,  VENIANT-ELLISON, Murielle M. ,  KOMOROWSKI, Renee ,  AGRAWAL, Neeraj ,  BATES, Darren L. ,  CLAVETTE, Brandon C. P. ,  FOLTZ, Ian N. ,  HO, Shu-yin ,  MURAWSKY, Christopher ,  MIN, Xiaoshan ,  WANG, Zhulun

IPC: C07K16/28 ,  A61K38/26 ,  A61K39/395 ,  A61P3/10

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.